Pediatric Allergy And Asthma Meeting (PAAM) 2022

November 12−13, 2021, Virtual Meeting

Pediatric Allergy And Asthma Meeting (PAAM)

Pediatric Allergy And Asthma Meeting (PAAM)

No publication submitted this year

poster icon

Ligelizumab in adolescent patients with chronic spontaneous urticaria: Results from a dedicated phase 2b study

M. Alvaro-Lozano, B. E. Sekerel, P. Staubach, M. Maurer, M. Ben-Shoshan, A. Drollmann, A. Bienczak, M. Porter, T. Liu, A. Burciu, T. Severin

Oral presentation

2020

No publication submitted this year

2019

poster icon

Study design and rationale of a phase 2b dose-finding study of ligelizumab (QGE031) in adolescent patients with chronic spontaneous urticaria

A. Drollmann, M. Porter, N. Kataoka, S. Koehne-Voss, M. Maurer, P. Staubach, M. Ben-Shoshan, BE. Sekerel, R. Janocha, T. Severin

thumb icon

Ligelizumab is well tolerated and exhibits a safety profile similar to omalizumab and placebo in patients with chronic spontaneous urticaria

G. Sussman, M. Maurer, A. Giménez-Arnau, E. Hua, T. Severin, R. Janocha

Oral Presentation

2018

No publication submitted this year

Cookie Settings

© Copyright 2023 Novartis Pharma AG